铁缺乏作为心力衰竭的可修改风险因素:证据和建议
Maryam1,2, Treesa P Varghese3, B Tazneem1
1Department of Pharmacy Practice, Deccan School of Pharmacy, Nampally, Hyderabad, Telangana, India.
概括
缺铁 (ID) 在心力衰竭 (HF) 中很常见,并会使症状恶化. 静脉注射铁有效地改善了ID的HF患者的生活质量和运动能力,无论贫血状态如何.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 临床研究 临床研究
背景情况:
- 心力衰竭 (HF) 是一种具有高发病率和死亡率的慢性疾病.
- 缺铁 (ID) 是HF中普遍存在的并发症,即使没有贫血,也会影响运动能力和生活质量.
- 大约30-50%的HF患者患有ID,需要进行例行查和管理.
研究的目的:
- 审查HF中ID的病理生理学,诊断和临床影响.
- 根据指导方针和临床试验,提供基于证据的ID治疗建议.
主要方法:
- 目前文献的审查,包括关键的临床试验 (FAIR-HF,CONFIRM-HF,AFFIRM-AHF).
- 分析病理生理学基础,诊断标准和HF中ID的临床影响.
- 综合基于证据的建议,用于ID治疗HF.
主要成果:
- 静脉注射铁补充剂,特别是铁性碳酸,显著改善了HF患者的功能状态,症状和生活质量.
- 无论贫血状况如何,都观察到IV铁的益处.
- 口服铁在这种患者群体中显示出有限的疗效.
结论:
- 鉴定是HF中一个显著的,可治疗的并发症.
- 建议在慢性HF患者中进行ID的常规查.
- 已确认ID的症状患者的静脉铁疗法改善了以患者为中心的结果,应纳入标准HF护理.
相关概念视频
Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
Heart Failure I: Introduction
676
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
676
Heart Failure VII: Nursing Interventions
410
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
410
Heart Failure VI: Adjunct Therapies
246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246
Pathophysiology of Heart Failure
2.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.8K
Heart Failure II: Pathophysiology
704
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
704


